• Media

    1. NoImage
      Photo:

      Brain matters in multiple sclerosis

    2. NoImage
      Photo:

      Brain Atrophy and Multiple Sclerosis Media Fact Sheet

    3. NoImage
      Photo:

      About Multiple Sclerosis Media Fact Sheet

    4. NoImage
      Photo:

      About Gilenya® (fingolimod) Media Fact Sheet

    5. NoImage
      Photo:

      Gilenya: Addressing Four Key Measures of Multiple Sclerosis Media Fact Sheet

  • Related Documents

    1. Brain matters in multiple sclerosis

    2. Brain Atrophy and Multiple Sclerosis Media Fact Sheet

    3. About Multiple Sclerosis Media Fact Sheet

    4. About Gilenya® (fingolimod) Media Fact Sheet

    5. Gilenya: Addressing Four Key Measures of Multiple Sclerosis Media Fact Sheet

  • Related Links

  • Novartis announces presentation of data at AAN showing Gilenya® slowed the rate of brain volume loss in MS patients

    • MS patients have accelerated brain volume loss (up to 3-5 times faster than people without MS), which is associated with physical & cognitive loss of function

    • Data at AAN showed significantly more Gilenya-treated patients (vs. patients on placebo) had brain volume loss rates comparable to people without MS

    • Brain volume loss, one of the four key measures of MS disease activity, starts early in the disease and is a predictor of long-term disability


    Basel, April 30, 2014
    – Novartis announced today new data presented at the 66th American Academy of Neurology (AAN) Annual Meeting, which showed more patients with relapsing multiple sclerosis (MS) treated with Gilenya® (fingolimod) achieved an average annual rate of brain volume loss within the range of those expected for healthy adults of a similar age vs. those patients taking placebo1. Everybody loses brain volume (also referred to as “shrinkage of the brain”) as they age1,2, but people with MS experience shrinkage of the brain up to three to five times faster1-4. This acceleration starts early in people with relapsing MS, even before symptoms are apparent5-8

    “These data are impressive as they show that Gilenya slows brain volume loss in relapsing MS patients, an important indicator of disease activity,” said David Epstein, Division Head, Novartis Pharmaceuticals. “Brain volume loss is a topic of growing interest to the MS community as reducing it may benefit patients by slowing long term physical and cognitive loss of function.”

    Based on growing evidence, damage from lesions and brain volume loss leads to worsening of the symptoms for MS (e.g. problems walking or difficulties with mental tasks)
    5,9-11. Brain volume loss is  strongly associated with long-term disability4,5,11-13.

    About the data at AAN
    The average brain volume loss in people without MS ranges from 0.2% to 0.4% per year1,2, depending on age (as described in the literature). MS patients typically lose brain volume at an approximate rate of  0.5% to 1.35% per year1,3,4.

    Post hoc analyses presented at AAN showed that significantly more Gilenya treated patients had annual brain volume loss rates below 0.4% (within the range of people without MS), compared to placebo (37.2% vs 26.7% respectively, p=0.0001)
    1.This effect was consistent across different age groups1.
     
    About Multiple Sclerosis
    Multiple sclerosis (MS) is a chronic disorder of the central nervous system (CNS) that disrupts the normal functioning of the brain, optic nerve and spinal cord14. The evolution of MS results in an increasing loss of both physical (e.g. difficulty with walking) and cognitive (e.g. problems with mental tasks or memory) function15. This has a substantial negative impact on the approximately 2.3 million people worldwide affected by MS16, a disease that begins in early adulthood, most often between the ages of 20 and 4017.

    The loss of physical and cognitive function is driven by two main types of damage that both contribute to widespread loss of neurons (nerve cells in the brain and spinal cord that transmit impulses): discrete inflammatory lesions, focal damage, in the brain that can clinically manifest as relapses; and ongoing, more diffuse damage that starts early in the disease and causes the progressive loss of brain tissue, including neurons, and over time is associated with both physical and cognitive problems
    18-20.

    About Gilenya
    Gilenya is the only oral disease modifying therapy (DMT) that works on four key measures of multiple sclerosis (MS) disease activity – relapses, MRI lesions, brain volume loss and disability progression21-26.

    Gilenya reduces both the distinct inflammatory lesions in the brain (focal damage) that can clinically manifest as relapses, and the ongoing, underlying damage in the brain (diffuse damage) that starts early in the disease
    18-20,27-29. Diffuse damage often goes unnoticed, causes the loss of neurons and over time is associated with both physical and cognitive problems18-20. Gilenya’s reduction of both focal and diffuse damage is due to its impact on the inflammatory process (peripheral action) and its ability to enter the CNS and impact from within the CNS (central action)27-29. It is by addressing both focal and diffuse damage that the course of MS can be effectively impacted, helping to preserve a patient’s physical (e.g. difficulty with walking) and cognitive (e.g. problems with mental tasks or memory) function.

    To date, more than 91,500 patients worldwide have been treated with Gilenya in both clinical trial and post-marketing setting
    29

    About Novartis in Multiple Sclerosis
    Novartis is committed to the research and development of new treatment options to offer the right treatment to the right patient at the right time, to meet patients’ needs at every stage of disease with innovative and targeted drugs.

    In addition to its ongoing development program for Gilenya in primary progressive MS (PPMS), pediatric MS and chronic inflammatory demyelinating polyneuropathy (CIPD), the Novartis MS portfolio includes Extavia
    ® (interferon beta-1b for subcutaneous injection). Investigational compounds include BAF312 (siponimod), which is currently in Phase III clinical development and being developed as the first oral therapy for secondary progressive MS (SPMS), and VAY736, an anti-B-cell compound for MS that is currently being investigated in proof of concept studies. Novartis is also exploring the IL-17 pathway in MS.

  • Full Press Release

About Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines, over-the-counter and animal health products. Novartis is the only global company with leading positions in these areas. In 2013, the Group achieved net sales of USD 57.9 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 135,000 full-time-equivalent associates and sell products in more than 150 countries around the world. For more information, please visit http://www.novartis.com.


Media Contacts